攝護腺特異抗原檢測與台灣攝護腺癌發生率之關係
林柏宏、馮思中、劉忠一、甘弘成、虞凱傑、邵翊紘、張英勛、莊正鏗
林口長庚醫院 泌尿科
Prostate-Specific Antigen Testing Related to Rising Incidence of Prostate Cancer
Po-Hung Lin, See-Tong Pang, Chung-Yi Liu, Hung-Cheng Kan, Kai-Jie Yu, I-Hung Shao, Ying-Hsu Chang, Cheng-Keng Chuang
Division of Urology, Department of surgery, Chang Gung Memorial Hospital at Linkou
Purpose:
To investigate possible factors related to the significantly increasing incidence rate of prostate cancer in Taiwan using the Health and Welfare Database (HWD) from 2006 to 2013.
Materials and Methods:
We used HWD, a nationwide database of medical information, to assess the incidence of prostate cancer, utilization of prostate-specific antigen (PSA) test, and underlying diseases of patients and to evaluate if there was a common trend among these factors.
Results:
In total, 32,508 patients with newly diagnosed prostate cancer from 2006 to 2013 were identified. The incidence rate of prostate cancer per 100,000 men increased from 35.47 in 2006 to 52.87 in 2012. The number of patients with prostate cancer and underlying diseases related to metabolic syndrome increased every year. The number of total PSA tests and patients undergoing PSA testing, as well as average times of PSA testing per person in the whole population, increased every year. The average PSA test times of patients with newly diagnosed prostate cancer within 3 years before the diagnosis of prostate cancer also increased every year. There was a high correlation between the average PSA test times and the number of patients with newly diagnosed prostate cancer (r2=0.9734).
Conclusion:
The trends of incidence of prostate cancer, utilization of PSA testing, and underlying diseases related to metabolic syndrome at the diagnoses of cancer were similar, increasing every year in the study period. The results suggested that increasing use of PSA tests may increase the diagnosis of prostate cancers. Underlying diseases related to metabolic syndrome may also affect the incidence of prostate cancer.